Loading clinical trials...
Loading clinical trials...
BIO-LIBRA Clinical Study
The purpose of this registry is to prospectively assess outcomes of device-treated ventricular tachyarrhythmias and all-cause mortality in non-ischemic cardiomyopathy patients indicated for ICD or CRT-D implantation for the primary prevention of sudden cardiac death. Differences in outcomes will be evaluated by sex and by device type.
The BIO-LIBRA Study will gather information about women and men with non-ischemic cardiomyopathy who are treated with implanted ICD and CRT-D devices from many locations across the United States. The BIO-LIBRA Study will look at the results of treatment in women and men enrollees. The two primary goals are: 1) to learn if there are differences in treatment response based on the patient's sex; and 2) to learn if there are differences in patient outcomes based on device type. There is a special focus on women in the BIO-LIBRA Study. Usually, only about 25% of people in prior device studies have been women. Yet heart disease is the number-one cause of death for women - one in three deaths each year. The BIO-LIBRA Study would like to have a more balanced study which includes more women than in prior studies. The goal is for at least 40% of the people participating in the study to be women. The study will observe up to 1,000 women and men over a three-year period following the device implant. Utilizing information collected at annual doctor visits and scheduled transmission reports from the implanted device in between these visits, the BIO-LIBRA Study will be able to evaluate some of the common risks of non-ischemic cardiomyopathy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Southview Cardiovascular Associates
Birmingham, Alabama, United States
Cardiology Associates of Mobile
Fairhope, Alabama, United States
Eisenhower Desert Cardiology
Rancho Mirage, California, United States
UC Davis Medical Center
Sacramento, California, United States
Cardiology Associates Medical Group
Ventura, California, United States
Cardiovascular Institute of North Colorado
Greeley, Colorado, United States
University of Florida
Gainesville, Florida, United States
AdventHealth Orlando
Orlando, Florida, United States
Orlando Health, Inc.
Orlando, Florida, United States
BayCare Medical Group Cardiology
Safety Harbor, Florida, United States
Start Date
May 9, 2019
Primary Completion Date
November 19, 2024
Completion Date
November 19, 2024
Last Updated
November 22, 2024
1,000
ACTUAL participants
Lead Sponsor
Biotronik, Inc.
Collaborators
NCT07252687
NCT04843371
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions